- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis : Episode 10
BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
Heidi Crayton, MD, discusses the rationale for investigating Bruton tyrosine kinase inhibitors (BTKis) as a treatment for patients with multiple sclerosis and the current stage of development for evobrutinib, tolebrutinib, and other BTKis.
Video Player is loading.
EP: 1.Teaser: Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis
EP: 2.Multiple Sclerosis: Impact, Types, Pathophysiology, and Progression
EP: 3.Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
EP: 4.Examining Key Unmet Needs in Multiple Sclerosis
EP: 5.Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
EP: 6.MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
EP: 7.Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
EP: 8.Examining Challenges with Drug Switching and Step Therapy in MS Treatment
EP: 9.Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
Now Viewing
EP: 10.BTK Inhibitors' Rationale and Potential Role in Multiple Sclerosis Treatment
EP: 11.Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
EP: 12.Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
EP: 13.Multiple Sclerosis: Looking Toward the Future
Video content above is prompted by the following questions:
- What was the rationale for the investigation of Bruton tyrosine kinase inhibitors (BTKis) for use as treatment in patients with multiple sclerosis (MS)?
- What is the stage in development for evobrutinib, tolebrutinib and other BTKis?
- How might these therapies fit into treatment algorithms for different types of MS?
- How do payers see these therapies being integrated into treatment algorithms?
Related Videos
Multiple Sclerosis: Looking Toward the Future
Primary Progressive Multiple Sclerosis Treatment Landscape: Emerging Therapies
Updates in Recent Clinical Trials in the Treatment of Multiple Sclerosis
Typical Payer Coverage Criteria for Multiple Sclerosis Therapies
Examining Challenges with Drug Switching and Step Therapy in MS Treatment
Incorporating a Subcutaneous Novel Therapy into Multiple Sclerosis Treatment
MS Treatment Guidelines: Expert Insights on Updates and Decision-Making
Patient Satisfaction: Opportunity for Better Multiple Sclerosis Therapies
Examining Key Unmet Needs in Multiple Sclerosis
Assessing Limitations, Costs, Mobility and Cognition in Progressive Multiple Sclerosis
Related Content
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials
January 9th 2025Article
Data from a systematic review of 30 real-world studies show comparable discontinuation rates of ocrelizumab to those in pivotal clinical trials among patients with different types of multiple sclerosis (MS).
Read More
